Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers

Br J Cancer. 2002 Jun 17;86(12):1888-92. doi: 10.1038/sj.bjc.6600372.

Abstract

Promoter hypermethylation of CpG islands in tumour suppressor genes can lead to transcriptional inactivation. To investigate the association between methylation and expression at O6-methylguanine-DNA methyltransferase, we performed methylation-specific PCR and immunohistochemistry in 149 gastric carcinomas. Promoter methylation was found in 14.1% of tumours and loss of expression was detected in 11.4% of tumours. To examine correlation between the O6-methylguanine-DNA methyltransferase expression and the clinical data, we investigated O6-methylguanine-DNA methyltransferase expression in 315 consecutive gastric carcinomas. A similar frequency of loss of O6-methylguanine-DNA methyltransferase expression was confirmed in these cases. The loss of O6-methylguanine-DNA methyltransferase expression was significantly associated with pTNM stage (P=0.037), tumour invasion (P=0.02), microsatellite instability (P=0.041) and overall survival (P=0.01). Among 11 gastric cancer cell lines, SNU-620 showed the loss of O6-methylguanine-DNA methyltransferase expression as well as promoter methylation. After treatment with 5-aza-2-deoxycytidine, a demethylating agent, SNU-620 re-expressed O6-methylguanine-DNA methyltransferase mRNA. In summary, we suggest that during gastric carcinogenesis, the loss of O6-methylguanine-DNA methyltransferase expression frequently occurs via the hypermethylation of the CpG islands of the promoter region, and that this is significantly associated with the clinicopathological characteristics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Azacitidine / analogs & derivatives*
  • Azacitidine / pharmacology
  • Carcinoma / enzymology
  • Carcinoma / genetics*
  • Carcinoma / pathology
  • CpG Islands / genetics*
  • DNA Methylation*
  • DNA Modification Methylases / antagonists & inhibitors
  • DNA Primers / chemistry
  • Decitabine
  • Down-Regulation
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Microsatellite Repeats / genetics
  • Mutation
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • O(6)-Methylguanine-DNA Methyltransferase / genetics
  • O(6)-Methylguanine-DNA Methyltransferase / metabolism*
  • Prognosis
  • Promoter Regions, Genetic
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sequence Analysis, DNA
  • Stomach / enzymology
  • Stomach Neoplasms / enzymology
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / pathology
  • Sulfites / pharmacology
  • Survival Rate
  • Transcription, Genetic
  • Tumor Cells, Cultured

Substances

  • Antimetabolites, Antineoplastic
  • DNA Primers
  • Enzyme Inhibitors
  • RNA, Messenger
  • Sulfites
  • Decitabine
  • DNA Modification Methylases
  • O(6)-Methylguanine-DNA Methyltransferase
  • Azacitidine
  • sodium bisulfite